Cardiac Sarcoidosis
34
12
13
10
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
11.8%
4 terminated out of 34 trials
71.4%
-15.1% vs benchmark
9%
3 trials in Phase 3/4
40%
4 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 10 completed trials
Clinical Trials (34)
Cardiac Sarcoidosis Randomized Trial
Cardiac Sarcoidosis Multi-Center Prospective Cohort
Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis
Exosome-based Omic Signatures of Disease Activity in Cardiac Sarcoidosis (EXODACS)
[68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation
Mayo AVC Registry and Biobank
Repurposing Tilmanocept for Cardiac Sarcoidosis
Development and Validation of a Health-related Quality of Life Tool for Patients With Cardiac Sarcoidosis
A Trial of Baricitinib in Patients With Cardiac Sarcoidosis
Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques
Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression
Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition
Rilonacept in Subjects With Cardiac Sarcoidosis
Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis
Evaluation of the Impact of a Patient Education Protocol on the Quality of 18F-FDG PET Imaging Indicated for Investigation of Cardiac Inflammation
Evaluation of the Prognostic Value of PET/MRI in Cardiac Sarcoidosis
UTSW HP [13-C] Pyruvate Injection in HCM
Routine Cardiac Screening in Sarcoidosis Patients
Inflammatory Cardiomyopathy Bern Registry
Somatostatin Receptor Imaging in Acute Myocarditis and Cardiac Sarcoidosis